JMP Securities Reaffirms “Buy” Rating for Axovant Sciences (AXON)

Share on StockTwits

JMP Securities reissued their buy rating on shares of Axovant Sciences (NASDAQ:AXON) in a report released on Monday morning. JMP Securities currently has a $6.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also recently issued reports on the stock. Jefferies Financial Group raised shares of Axovant Sciences from a hold rating to a buy rating and set a $3.00 price objective on the stock in a research note on Monday, December 17th. BidaskClub raised shares of Axovant Sciences from a strong sell rating to a sell rating in a research note on Tuesday, October 16th. ValuEngine raised shares of Axovant Sciences from a hold rating to a buy rating in a research report on Thursday, November 1st. Oppenheimer reissued a hold rating on shares of Axovant Sciences in a research report on Sunday, November 11th. Finally, Zacks Investment Research raised shares of Axovant Sciences from a hold rating to a buy rating and set a $1.25 price target on the stock in a research report on Monday, January 7th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. Axovant Sciences presently has an average rating of Hold and a consensus target price of $4.25.

Shares of AXON stock opened at $1.22 on Monday. Axovant Sciences has a 52-week low of $0.93 and a 52-week high of $6.59. The company has a market capitalization of $157.74 million, a price-to-earnings ratio of -0.59 and a beta of 1.21. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 1.24.

Axovant Sciences (NASDAQ:AXON) last announced its quarterly earnings data on Thursday, February 7th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.27). As a group, equities analysts anticipate that Axovant Sciences will post -1.25 earnings per share for the current year.

In other news, major shareholder Svf Investments (Uk) Ltd purchased 10,000,000 shares of Axovant Sciences stock in a transaction dated Tuesday, December 18th. The shares were bought at an average cost of $1.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the insider now directly owns 99,285,714 shares in the company, valued at approximately $99,285,714. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 6.00% of the company’s stock.

Large investors have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in shares of Axovant Sciences by 13.5% during the third quarter. BlackRock Inc. now owns 1,424,710 shares of the biotechnology company’s stock worth $3,447,000 after acquiring an additional 169,918 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Axovant Sciences by 60.5% during the third quarter. Renaissance Technologies LLC now owns 2,091,700 shares of the biotechnology company’s stock worth $5,062,000 after acquiring an additional 788,100 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Axovant Sciences by 12.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock worth $1,354,000 after acquiring an additional 64,152 shares during the period. Geode Capital Management LLC raised its holdings in shares of Axovant Sciences by 118.1% during the fourth quarter. Geode Capital Management LLC now owns 95,087 shares of the biotechnology company’s stock worth $94,000 after acquiring an additional 51,499 shares during the period. Finally, GSA Capital Partners LLP raised its holdings in shares of Axovant Sciences by 22.9% during the fourth quarter. GSA Capital Partners LLP now owns 156,795 shares of the biotechnology company’s stock worth $156,000 after acquiring an additional 29,200 shares during the period. Institutional investors and hedge funds own 7.58% of the company’s stock.

Axovant Sciences Company Profile

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Featured Article: What is a Roth IRA?

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.